<DOC>
	<DOC>NCT02564198</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.</brief_summary>
	<brief_title>A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Part A: participants with recurrent or refractory nonCNS solid tumors Part B: participants with recurrent or refractory CNS tumors Measurable or evaluable disease No other therapeutic options Performance Status: Karnofsky ≥50% for participants &gt;16 years and Lansky ≥50 for participants ≤16 years Active or recent history of serious bleeding events Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses Active or recent history of hypertensive crisis or hypertensive encephalopathy Active nonhealing wound or bone fracture History of solid organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>relapsed pediatric solid tumors</keyword>
	<keyword>unspecified childhood solid tumor</keyword>
	<keyword>brain and central nervous system tumors</keyword>
</DOC>